The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Risdiplam shown to improve motor function in people aged 2 to 25 with type 2 or 3 SMA

    Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy First placebo-controlled trial to include adults with SMA demonstrates risdiplam improved or stabilised motor function Medically meaningful and statistically significant results in primary and key secondary endpoints Pivotal SUNFISH Part 2 study population represents broad, […]


  2. FDA grants priority review to risdiplam for the treatment of SMA

    The United States’ Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of SMA. The FDA’s decision will be announced on 24th May 2020. If approved, risdiplam, an orally administered liquid, would be the first at-home administered medicine for people living with SMA. […]